1.24
+0.14(+12.73%)
Currency In USD
Address
200 Powder Mill Road
Wilmington, DE 19803
United States of America
Phone
302 467 1280
Website
Sector
Healthcare
Industry
Biotechnology
Employees
131
First IPO Date
September 25, 2020
| Name | Title | Pay | Year Born |
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, Chief Executive Officer & Director | 881,092 | 1966 |
| Dr. Andrew P. Combs Ph.D. | Executive Vice President & Chief Chemistry Officer | 562,461 | 1967 |
| Mr. Bryant David Lim J.D. | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 621,017 | 1971 |
| Dr. Edna Huang M.D. | President & Chief Medical Officer | 843,233 | 1973 |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer | 868,617 | 1962 |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations | 0 | N/A |
| Dr. William B. Novotny M.D. | Senior Vice President of Clinical Development | 0 | N/A |
| Mr. Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine | 0 | N/A |
| Ms. Aimee Crombie Ph.D. | Senior Vice President and Head of Strategic Planning & Operations | 0 | N/A |
| Ms. Michele Porreca M.B.A. | Chief People Officer | 0 | N/A |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.